PLoS Pathogens (Feb 2019)

Casting a wider net: Immunosurveillance by nonclassical MHC molecules.

  • M Patricia D'Souza,
  • Erin Adams,
  • John D Altman,
  • Michael E Birnbaum,
  • Cesar Boggiano,
  • Giulia Casorati,
  • Yueh-Hsiu Chien,
  • Anthony Conley,
  • Sidonia Barbara Guiomar Eckle,
  • Klaus Früh,
  • Timothy Gondré-Lewis,
  • Namir Hassan,
  • Huang Huang,
  • Lakshmi Jayashankar,
  • Anne G Kasmar,
  • Nina Kunwar,
  • Judith Lavelle,
  • David M Lewinsohn,
  • Branch Moody,
  • Louis Picker,
  • Lakshmi Ramachandra,
  • Nilabh Shastri,
  • Peter Parham,
  • Andrew J McMichael,
  • Jonathan W Yewdell

DOI
https://doi.org/10.1371/journal.ppat.1007567
Journal volume & issue
Vol. 15, no. 2
p. e1007567

Abstract

Read online

Most studies of T lymphocytes focus on recognition of classical major histocompatibility complex (MHC) class I or II molecules presenting oligopeptides, yet there are numerous variations and exceptions of biological significance based on recognition of a wide variety of nonclassical MHC molecules. These include αβ and γδ T cells that recognize different class Ib molecules (CD1, MR-1, HLA-E, G, F, et al.) that are nearly monomorphic within a given species. Collectively, these T cells can be considered "unconventional," in part because they recognize lipids, metabolites, and modified peptides. Unlike classical MHC-specific cells, unconventional T cells generally exhibit limited T-cell antigen receptor (TCR) repertoires and often produce innate immune cell-like rapid effector responses. Exploiting this system in new generation vaccines for human immunodeficiency virus (HIV), tuberculosis (TB), other infectious agents, and cancer was the focus of a recent workshop, "Immune Surveillance by Non-classical MHC Molecules: Improving Diversity for Antigens," sponsored by the National Institute of Allergy and Infectious Diseases. Here, we summarize salient points presented regarding the basic immunobiology of unconventional T cells, recent advances in methodologies to measure unconventional T-cell activity in diseases, and approaches to harness their considerable clinical potential.